Stock Market Blog
Daily stock market analysis, trade alerts, and trading education from Ross Givens and the Traders Agency team.
TradingView Review
Our tradingview review breaks down charting, Pine Script, and pricing to see if it's safe, worth it, and good for day trading.
TradingView Chart Setup for Beginners
Learn the tradingview chart setup beginners use: indicators, layouts, alerts, and saving your workspace for repeatable analysis.
Novo Shares Fall Up to 7% as Drugmaker's 2030 Growth Ambitions Disappoint Investors
Novo shares fell as much as 7% after the drugmaker's Capital Markets Day 2030 ambitions and diversification plan fell short of investor hopes, with analysts flagging growth only in line with pharma peers.
SoftBank Launches $10 Billion and €1 Billion Bond Sale to Fund Third OpenAI Tranche
SoftBank has launched $10 billion of dollar notes and €1 billion of euro notes, mainly to fund the third $10 billion tranche of its OpenAI investment, with Fitch assigning a BB+ rating as borrowing costs rise, per term sheet reporting.
Ireland's Data Protection Commission Fines Google €403m Over Location Data Processing
Ireland's Data Protection Commission has fined Google €403 million ($463 million, per Reuters) over its processing of users' location data and ordered compliance within six months, RTÉ and Reuters reported. Google says the case concerns historical policies since updated.
Stock Market Today: Technology Leads While S&P 500 Advances
Technology led the session while the S&P 500 advances. See the validated market scorecard, sector performance, and what traders are watching next.
Trade This Not That
Everybody has a theory about where this pullback goes next. The harder part is knowing when the market itself starts proving them wrong.
Lilly Says Updated EMBER-3 Data Show Imlunestrant-Abemaciclib Nearly Doubled Progression-Free Survival; Combination Submitted for U.S. Review
Lilly's updated Phase 3 EMBER-3 results show imlunestrant plus abemaciclib delivered median progression-free survival of 10.9 months versus 5.5 months for imlunestrant alone. The combination is not approved in the U.S.; Lilly says it has submitted the data for regulatory review.
Volkswagen Cuts 2026 Profit Guidance as China Slump and Porsche Impairment Bite
Volkswagen cut its 2026 profit guidance in September, per Seeking Alpha, citing weak China sales, underperforming brands and a Porsche AG goodwill impairment, after a July cut to its revenue outlook alongside a 32.9% drop in Q2 net profit.
The BEST Buying Opportunity in 50 Years Is Here
Is this a real stock market buying opportunity or the riskiest setup in 25 years? See why index buyers should rethink strategy now.
Boeing's Revised SPEEA Offer Adds Immediate 10% Raise as Union Negotiators Recommend Acceptance
Boeing's revised final offer to SPEEA includes an immediate 10% guaranteed wage increase, and union negotiators are recommending ratification after members rejected an earlier package on Aug. 21.
MISTRAS Group to Go Private in $866 Million H.I.G. Capital Deal at $20.35 a Share
MISTRAS Group has agreed to an all-cash sale to H.I.G. Capital at $20.35 a share, an enterprise value of about $866 million, with a 40-day go-shop running to October 27 and roughly 31% of shares locked up in support.
Stop watching.
Start winning.
50,000+ traders get our daily brief before the market opens.
You're subscribed!
Check your inbox.
Free. No spam. Unsubscribe anytime.
